Kalyan Ram Bhamidimarri
YOU?
Author Swipe
View article: Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections—Results from the ICA “Global Study” (EABCIR-Global Study)
Determinants of clinical response to empirical antibiotic treatment in patients with cirrhosis and bacterial and fungal infections—Results from the ICA “Global Study” (EABCIR-Global Study) Open
Background: The administration of an appropriate empirical antibiotic treatment is essential in cirrhosis and severe bacterial infections. We aimed to investigate the predictors of clinical response of empirical antibiotic treatment in a p…
View article: Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes Open
Hepatic encephalopathy (HE) is a serious neurocognitive complication of liver dysfunction, often associated with elevated plasma ammonia. Ornithine phenylacetate (OP), a potent ammonia scavenger, is being evaluated for the treatment of acu…
View article: Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial
Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial Open
In a randomized controlled trial of patients with cirrhosis and HE, we found no significant difference in time to clinical improvement between patients given OP vs placebo. However, OP appears to be safe and should undergo further testing …
View article: Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff?
Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff? Open
Background. The aging of liver transplant (LT) recipients, the weighting of the model for end-stage liver disease score, and the increased prevalence of nonalcoholic steatohepatitis has led to an increased number of older LT recipients wit…
View article: Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis
Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis Open
Nonalcoholic steatohepatitis (NASH) is one of the top 3 indications for liver transplantation (LT) in Western countries. It is unknown whether renal dysfunction at the time of LT has any effect on post‐LT outcomes in recipients with NASH. …
View article: Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis
Randomized, Double‐Blind, Placebo‐Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis Open
Preimplantation factor (PIF) is an evolutionary conserved peptide secreted by viable embryos which promotes maternal tolerance without immune suppression. Synthetic PIF (sPIF) replicates native peptide activity. The aim of this study was t…
View article: Hepatitis B Virus Infection and Organ Transplantation.
Hepatitis B Virus Infection and Organ Transplantation. Open
Hepatitis B virus (HBV) infection remains an important cause of liver disease and continues to present several unique challenges in organ transplantation despite the availability of an effective vaccine to prevent HBV infection and the int…
View article: Erratum: A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis
Erratum: A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis Open
The author name: Shivali R. Berera, MD Should be corrected to read: Shivali Berera, MD The middle initial R. was erroneously added during copyediting.
View article: Hepatitis C Virus and Liver Transplantation.
Hepatitis C Virus and Liver Transplantation. Open
Hepatitis C virus (HCV) is a major cause of death from infectious disease and is still the leading indication for liver transplantation in the United States and other Western countries. All-oral, direct-acting antiviral (DAA) therapies hav…
View article: Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study Open
The availability of direct acting antiviral agents (DAA) has transformed the treatment of hepatitis C virus (HCV) infection. The current study is a case series that reports the outcomes from a cohort of twenty-five HCV-infected ESRD patien…
View article: Erratum: A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis
Erratum: A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis Open
The author name: Shivali R. Berera, MD Should be corrected to read: Shivali Berera, MD The middle initial R. was erroneously added during copyediting.
View article: Clinical Outcomes in HIV+/HCV+ Co-infected Kidney Transplant Recipients in the Pre- and Post-direct Acting Antiviral (DAA) Therapy Eras: 10-year Single-center Experience
Clinical Outcomes in HIV+/HCV+ Co-infected Kidney Transplant Recipients in the Pre- and Post-direct Acting Antiviral (DAA) Therapy Eras: 10-year Single-center Experience Open
Clinical outcomes in HIV+/HCV+ co-infected kidney transplant recipients in the pre- and post-direct acting antiviral (DAA) therapy eras: 10 year Single-center experience Previous studies have shown worse patient and graft survival followin…
View article: Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease
Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease Open
The prevalence of Hepatitis C (HCV) in patients with advanced renal disease and dialysis is higher than that of general population with rates around 5–10% in Europe and USA (1,2).
View article: A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis
A Rare Case of Hepatitis C-Associated Cryoglobulinemic Duodenal Vasculitis Open
Intestinal involvement of cryoglobulinemia is an uncommon manifestation and marker of severe vasculitis. We describe the case of a woman admitted to our service for management of acute renal failure and progressive gastrointestinal symptom…